Abeona Therapeutics(us:ABEO)

4.45

-6.51%

Updated on 2025-04-02

Open:4.74
Close:4.45
High:4.74
Low:4.42
Prev Close:4.76
Volume:959517.00
Turnover:4.33M
Turnover Ratio:1.98%
Shares:48.53M
MarketCap:215.98M
DateTotalTotal SharesTotal RatioNewIncreasedDecreased
2024-06-30673361266680.68%122528
2024-03-31631444938452.45%152318
2023-12-31541414068853.31%141517
2023-09-30461247703450.49%91411
2023-06-3042939280243.73%9813
2023-03-3145752588941.98%41018
2022-12-3144817413346.13%19910
2022-09-3046210497327.44%5333
dateorgNametotalratiochangeShareschangeRatio
2024-03-31Adage Capital Partners Gp, L.L.C.324999411.80%0
2024-03-31Nantahala Capital Management, Llc23106408.39%603882.68%
2024-03-31Millennium Management Llc19865487.21%56787340.03%
2024-03-31Western Standard Llc13614894.94%55337768.48%
2024-03-31Vanguard Group Inc11019584.00%8270.07%
2024-03-31Ikarian Capital, Llc8885933.23%28859348.10%
2024-03-31Laurion Capital Management Lp6468302.35%646830
2024-03-31Citigroup Inc4840541.76%337077.49%
2024-03-31Boothbay Fund Management, Llc2703400.98%11008068.69%
2024-03-31Walleye Capital Llc2661140.97%7809841.54%

About

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Address:6555 Carnegie Avenue,4th floor

Market Movers